Company Profiles‎ > ‎


KAHR Medical is pioneering the development of a new class of therapeutic drugs named Trans Signal Converter Proteins (TSCPs): fusion proteins with two functional ends. The TSCP’s unique structure can be translated to higher efficacy and specificity in disease treatment.

KAHR’s lead product, KAHR-101, is in pre-clinical development and shows great promise in the treatment of cancer and autoimmune diseases in multiple animal models.

The company has initiated a Series-A fundraising round to finance a Phase-I/II trial with KAHR-101 in cancer patients.


TSCPs are fusion proteins with two functional ends and are the first class of drugs capable of converting trans-cellular signals.

KAHR has licensed the TSCP technology from the University of Pennsylvania and selected four molecules for drug development. KAHR’s intellectual property covers a vast number of TSCP molecules, each directed at multiple cancer and autoimmune indications.

The TSCP technology has been studied for a decade, mostly at the University of Pennsylvania and the Hadassah Medical Center, and its therapeutic promise has been documented in multiple scientific publications.

For KAHR-101, the company has developed a complete production process and has demonstrated its mode-of-action and  clear efficacy in animal models of liver and renal cancer, multiple sclerosis (MS), and rheumatoid arthritis (RA). KAHR-101 is set for clinical development and KAHR plans a Phase-I/II trial in cancer patients at the Hadassah Medical Center.

Contact Details
Address: Hadassah Medical Center, POB 12000, Jerusalem 91120
Phone: 972-525-989878
Fax : 972-4629-2112
Internet Site: 

Exhibition Representative
Name: Noam Shani
Mobile: 972-525-989878

Category: Pharmaceutical/Biopharmaceutical